SUBSTIPHARM

Company snapshot

Substipharm is a privately held pharmaceutical Group. We develop, supply and commercialize pharmaceuticals in more than 90 countries worldwide. Our portfolio of products that we currently license out or distribute directly or through partners comprises more than 90 different molecules. Our development pipeline includes as well more than 50 ongoing projects. We have a successful portfolio of pharma

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SUBSTIPHARM. Not investment advice.

• What is SUBSTIPHARM?

  Substipharm is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include None - Healthy subjects. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USP

• Is SUBSTIPHARM publicly traded?

  SUBSTIPHARM appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does SUBSTIPHARM develop or market?

  We link 3 drug profile(s) where SUBSTIPHARM is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/substipharm#company-drugs.

• What are the latest developments for SUBSTIPHARM?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does SUBSTIPHARM focus on?

  SUBSTIPHARM focuses on None - Healthy subjects based on our analysis of their pipeline programs and drug development activities.